OR51E1

Across TCGA pan-cancer cohorts, OR51E1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated OR51E1 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher OR51E1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated OR51E1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LIHC, SKCM, and UCS are the cancer types where OR51E1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	III,IV	0.077	0.414	.004	9	view →
SKCM	OS	Median	All	1.000	0.865	.011	7	view →
UCS	OS	Median	All	0.153	0.687	.019	6	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

OR51E1–LIHC (DFS)

Open the LIHC breakdown →